Cocrystal pharma receives pre-ind responses from the fda on oral cc-42344 for treating influenza a

Feedback provides greater clarity on regulatory requirements for planned phase 2b trial bothell, wash., march 19, 2024 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces it has received pre-investigational new drug (pre-ind) feedback from the u.s. food and drug administration (fda) regarding cc-42344 as a potential oral treatment for pandemic and seasonal influenza a.
COCP Ratings Summary
COCP Quant Ranking